On June 15, 2020, the Food and Drug Administration (FDA) approved Zepzelca (lurbinectedin) for treatment of advanced small cell lung cancer (SCLC) whose cancer has progressed after platinum chemotherapy. The FDA based their approval on the results of a [...]